The effect of sitagliptin or alogliptin on blood glucose levels and vascular endothelial function in type2 diabetes

The effect of sitagliptin or alogliptin on blood glucose levels and vascular endothelial function in type2 diabetes - SILVER

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011117

Enrollment

Registered

2013-07-04

Start date

2013-07-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Sitagliptin Group (Sample size 10 ) 3Months Alogliptin Group (Sample size 10 ) 3Months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes mellitus hemoglobin A1c 6.5% and above (NGSP)

Exclusion criteria

Exclusion criteria: 1)Serum creatine levels are 1.5mg/dL (male)and 1.3mg/dL(female) or more. 2)Patients with taking glinides or GLP-1 3) Patients sufferd from severe ketosis, diabetic coma or semi-coma within 6- month before participating the study 4) Patients sufferd from severe infection or trauma, and perioperative 5)Possible or definitive pregnant women or nursing mother 6) Patients with history of hypersensitivity to any ingredients of sitagliptin and alogliptin tablets 7)Patients with taking DPP-4 Inhibitor Other patients deemed not appropliate for participating to the study by investigators

Design outcomes

Primary

Measure	Time frame
The change of HbA1c levels and rate	—

Countries

Japan

Contacts

Public ContactYoshihiro Yamada

Fukuoka Tokushukai Hospital Department of Cardiology

y_yuko@csf.ne.jp092-573-6622

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026